Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Results of ProstateCancerScreening in a Unique Cohort at 19yr of Follow-up We assessed the effect of screening in the European Randomized study of Screening for ProstateCancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm (...) with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostatecancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could
Prostatecancerscreening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer.Systematic review and meta-analysis.Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018.Randomised controlled trials (...) mortality (IRR 0.99, 95% CI 0.98 to 1.01; moderate certainty) and may have no effect on prostate-specific mortality (IRR 0.96, 0.85 to 1.08; low certainty). Sensitivity analysis of studies at lower risk of bias (n=1) also demonstrates that screening seems to have no effect on all-cause mortality (IRR 1.0, 0.98 to 1.02; moderate certainty) but may have a small effect on prostate-specific mortality (IRR 0.79, 0.69 to 0.91; moderate certainty). This corresponds to one less death from prostatecancer per
Prostatecancerscreening Top results for prostatecancerscreening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search (...) might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostatecancerscreening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance
Screening for ProstateCancer: US Preventive Services Task Force Recommendation Statement. In the United States, the lifetime risk of being diagnosed with prostatecancer is approximately 13%, and the lifetime risk of dying of prostatecancer is 2.5%. The median age of death from prostatecancer is 80 years. Many men with prostatecancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostatecancer (...) have an increased risk of prostatecancer compared with other men.To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostatecancer and subsequent treatment of screen-detected prostatecancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening
Prostate-Specific Antigen-Based Screening for ProstateCancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Prostatecancer is the second leading cause of cancer death among US men.To systematically review evidence on prostate-specific antigen (PSA)-based prostatecancerscreening, treatments for localized prostatecancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force.Searches of PubMed, EMBASE, Web of Science, and Cochrane (...) investigators independently rated study quality.Prostate cancer and all-cause mortality; false-positive screening results, biopsy complications, overdiagnosis; adverse effects of active treatments. Random-effects meta-analyses were conducted for treatment harms.Sixty-three studies in 104 publications were included (N = 1 904 950). Randomization to PSA screening was not associated with reduced risk of prostatecancer mortality in either a US trial with substantial control group contamination (n = 76 683
ProstateCancer: Screening Final Update Summary: ProstateCancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 22.214.171.1248 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Is ProstateCancerScreening Right For You? (794 KB, ) ProstateCancer: Screening Release Date: May 2018 Recommendation Summary Population Recommendation Grade Men aged 55 to 69 years For men aged 55 to 69 years, the decision to undergo periodic prostate-specific (...) antigen (PSA)–based screening for prostatecancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostatecancer in some men. However, many men will experience potential harms of screening, including false-positive results
Effect of a Low-Intensity PSA-Based Screening Intervention on ProstateCancer Mortality: The CAP Randomized Clinical Trial. Prostatecancerscreening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostatecancer-specific mortality.The Cluster Randomized Trial of PSA Testing (...) stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostatecancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSA screening clinic.Among 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included in the analysis (n = 408 825; 98%). In the intervention group, 75 707 (40%) attended the PSA testing clinic and 67 313
Polygenic hazard score to guide screening for aggressive prostatecancer: development and validation in large scale cohorts. To develop and validate a genetic tool to predict age of onset of aggressive prostatecancer (PCa) and to guide decisions of who to screen and at what age.Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age (...) at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction
Screening for ProstateCancer* Screening for ProstateCancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for ProstateCancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostatecancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr
Reconciling the Effects of Screening on ProstateCancer Mortality in the ERSPC and PLCO Trials. The ERSPC (European Randomized Study of Screening for ProstateCancer) found that screening reduced prostatecancer mortality, but the PLCO (Prostate, Lung, Colorectal, and Ovarian CancerScreening Trial) found no reduction.To evaluate whether effects of screening on prostatecancer mortality relative to no screening differed between the ERSPC and PLCO.Cox regression of prostatecancer death in each (...) trial group, adjusted for age and trial. Extended analyses accounted for increased incidence due to screening and diagnostic work-up in each group via mean lead times (MLTs), which were estimated empirically and using analytic or microsimulation models.Randomized controlled trials in Europe and the United States.Men aged 55 to 69 (ERSPC) or 55 to 74 (PLCO) years at randomization.Prostate cancer screening.Prostate cancer incidence and survival from randomization; prostatecancer incidence
EAU-ESTRO-SIOG Guidelines on ProstateCancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostatecancer (PCa).The working panel performed a literature review of the new data (...) guidelines endorsed by the European Society for Radiotherapy and Oncology and the International Society of Geriatric Oncology and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office and online (http://uroweb.org/guideline/prostate-cancer/).The 2016 EAU-STRO-IOG ProstateCancer (PCa) Guidelines present updated information on the diagnosis, and treatment of clinically localised prostatecancer. In Northern and Western Europe, the number of men diagnosed
Psychological Predictors of ProstateCancerScreening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy Prostatecancer is the fourth most common cancer worldwide and is the second most lethal cancer.The aim of this study was to investigate psychological predictors of prostatecancerscreening behaviors among men over 50 years of age in Hamadan.This cross-sectional study was carried out on 200 men over 50 years of age in Hamadan, west of Iran. Participants were (...) recruited with a cluster sampling method. The subjects completed a self-administered questionnaire including demographic characteristics, prostatecancerscreening behaviors and psychological factors related to prostatecancer. Data was analyzed by SPSS-18 using chi-square, fisher exact test, and logestic regression.According to the results, 8.5 and 7.5 percent of participants reported history of digital rectal exam and prostate-specific antigen test, respectively. Also, the subjects reported 18.5
ProstateCancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. Prostatecancer incidence in men 75 years and older substantially decreased following the 2008 US Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this age group. It is unknown whether incidence has changed since the USPSTF recommendation against screening for all men in May 2012.To examine recent changes in stage-specific prostate (...) cancer incidence and PSA screening rates following the 2008 and 2012 USPSTF recommendations.Ecologic study of age-standardized prostatecancer incidence (newly diagnosed cases/100,000 men aged ≥50 years) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries and PSA screening rate in the past year among men 50 years and older without a history of prostatecancer who responded to the 2005 (n = 4580), 2008 (n = 3476), 2010 (n
Prostate-Specific Antigen (PSA)?based population screening for prostatecancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis Tawfik A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Tawfik A. Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an economic analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(11). 2015 Authors' conclusions PSA screening is associated with significant costs to the health care system when the cost of the PSA test itself is considered in addition to the costs of diagnosis, staging, and treatment of screen-detected PCs. Final publication URL Indexing Status
Prostate-Specific Antigen (PSA)?based population screening for prostatecancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostatecancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs
Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms (...) of Prostate-Specific Antigen (PSA) screening in prostatecancer: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions Based on the evidence, the following conclusions can be made: There are major harms (unnecessary risks) associated with PSA screening, including: • harms associated with prostate biopsy • overdiagnosis There are minor harms associated with PSA screening including: • harms associated with PSA testing PSA-based screening for prostatecancer results
Factors associated with prostatecancerscreening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model Prostatecancer is one of the most common and lethal cancers in the world. The incidence of prostatecancer has been increasing in recent years. The purpose of this study was to investigate factors associated with prostatecancerscreening behaviors among men over 50 in Fasa, Iran, based on the PRECEDE model.In this cross-sectional study, 400 men over 50 were studied in Fasa (...) , Iran. Data were collected via a questionnaire on demographic characteristics, such as age, number of children, occupation, education, marital status, smoking, and prostatecancerscreening behaviors. Data were analyzed using SPSS software, version 16. Independent samples t-test and the Pearson Product Moment correlation coefficient were used for the statistical analyses.Men in the study had little knowledge (34.11±8.22) and attitude (28.23±7.23) about prostatecancer and screening behavior
Prostate-Specific Antigen?Based Population Screening for ProstateCancer PSA-Based Population Screening for ProstateCancer: OHTAC Recommendation. May 2015; pp. 1–5 Prostate-Specific Antigen (PSA)–Based Population Screening for ProstateCancer: OHTAC Recommendation HEALTH QUALITY ONTARIO ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATION OHTAC recommends against the introduction of a formal, population-based PSA screening program for prostatecancer in Ontario. BACKGROUND Prostate (...) Population Screening for ProstateCancer: OHTAC Recommendation. May 2015; pp. 1–5 2 average-risk males reduces prostatecancer mortality or overall mortality, increases the detection of prostatecancer, or decreases the rate of aggressive or metastatic cancers? A systematic search of trials published between 2008 and 2013, specifically systematic reviews and randomized controlled trials (RCT) of PSA-based population screening programs, identified 11 reports, including 5 systematic reviews and 6 RCTs